Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-045790
Filing Date
2024-11-14
Accepted
2024-11-14 16:01:51
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2890529
2 ex31-1.htm EX-31.1 12857
3 ex31-2.htm EX-31.2 12814
4 ex32-1.htm EX-32.1 8145
  Complete submission text file 0001493152-24-045790.txt   8056482

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE gnlx-20240930.xsd EX-101.SCH 45028
6 XBRL CALCULATION FILE gnlx-20240930_cal.xml EX-101.CAL 47887
7 XBRL DEFINITION FILE gnlx-20240930_def.xml EX-101.DEF 187762
8 XBRL LABEL FILE gnlx-20240930_lab.xml EX-101.LAB 421210
9 XBRL PRESENTATION FILE gnlx-20240930_pre.xml EX-101.PRE 297659
60 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1022599
Mailing Address 2625 TOWNSGATE ROAD, SUITE 230 WESTLAKE VILLAGE CA 91361
Business Address 2625 TOWNSGATE ROAD, SUITE 230 WESTLAKE VILLAGE CA 91361 805-267-9889
GENELUX Corp (Filer) CIK: 0001231457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41599 | Film No.: 241461580
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)